A Phase 3 interventional study of Quetiapine fumarate and Risperidone in Schizophrenia, sponsored by AstraZeneca. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2009-06-11.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing quetiapine in Schizophrenia — none open to participants now, none under way, none of them phase 3. quetiapine · Schizophrenia.
Among the 70 studies testing quetiapine in Schizophrenia, this one is the 51st largest by enrollment of the 67 interventional ones that give a count, is one of 3 that started in 2001, is one of 25 in phase 3, and was the 27th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →None of the 70 studies testing quetiapine in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →
quetiapine: first FDA approval 1997 (SEROQUEL). What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 3 · Phase 3 26 · Phase 4 33
First in 1997; this study’s year is marked. 3 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is below the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 100 across the 67 interventional studies. Of the 62 that completed or were terminated, 17 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 70 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
79 studies in Schizophrenia by AstraZeneca: none open now, none under way, none of them phase 3. Of 79 finished, 14 (18%) have results posted.
Among the 79 studies in Schizophrenia by AstraZeneca, this one is the 27th largest by enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2001, is one of 20 in phase 3, and was the 17th registered.
AstraZeneca’s Schizophrenia studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 70 studies testing quetiapine in Schizophrenia, from their registry updates:
Among AstraZeneca’s 79 in Schizophrenia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to investigate the outcome on negative symptoms of schizophrenic patients during therapy with quetiapine or risperidone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
For the subset of subjects for the fMRI investigations the following additional exclusion criteria is valid as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinical efficacy of both neuroleptics, especially with regard to cognitive deficits and functional brain activation between baseline and week 12
Change from baseline in PANSS negative symptom total score, PANSS subscores, CGI, CGI-severity of illness, HAMD, Simpson-Angus-Scale, BPRS, specific PANSS items , Startle reflex.
The record gives a start of Nov 2001 and a completion of Jan 2003. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Quetiapine · Risperidone